Other Search Results
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Causes
- Diagnosis
- Other Disorders Associated ...
- Complications
- Treatment
- Medications
- Behavioral Management
- Other Treatments
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the Food and Drug Administration (FDA) approved lisdexamfetamine (Vysvanse), a new stimulant drug for the treatment of attention-deficit/hyperactivity disorder (ADHD). The active ingredient in lisdexamfetamine is similar to dextroamphetamine, the drug used in Dexedrine and Adderall.
Drug Warning
In 2007, the FDA instructed the manufacturers of all ADHD drugs to include drug warning labels describing the risks for heart and psychiatric side effects.
- 0 Comments